MFDS Approves 'Tabalis Tablets' for Immune Thrombocytopenia Treatment
New Therapeutic Opportunities Anticipated
The Ministry of Food and Drug Safety announced on the 20th that it has approved JW Pharmaceutical's rare drug, Tavalisse Tab 100 mg (Fostamatinib Disodium Hydrate), used for the treatment of adult immune thrombocytopenia.
Adult immune thrombocytopenia is an autoimmune disease in which antibodies against platelets are produced, leading to the destruction of platelets in the spleen, causing petechiae and purpura on the skin.
Tavalisse Tab treats this autoimmune disease by inhibiting the production of antibodies against platelets, preventing platelet destruction, and also blocking macrophage-mediated platelet phagocytosis. This treatment inhibits the activation of spleen tyrosine kinase, suppressing antibody production against platelets to prevent their destruction, while simultaneously interfering with macrophage platelet phagocytosis.
The Ministry of Food and Drug Safety expects this treatment to provide new therapeutic opportunities for patients who previously showed insufficient response to treatments for adult immune thrombocytopenia.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
The Ministry stated that it will continue to make every effort to ensure that new treatments for rare and intractable diseases are rapidly supplied to patients, expanding treatment opportunities based on regulatory science expertise.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
